Pomerantz investigates TriSalus over potential securities law violations
Pomerantz LLP is investigating TriSalus Life Sciences Inc. for potential securities fraud following a 41.56% stock decline. The company reported Q1 revenue of $8.90 million, a 2.92% year-over-year drop, and cut full-year guidance by $5.5 million at the midpoint due to delayed FDA clearance for its TriNav Advance product.
*this image is generated using AI for illustrative purposes only.
Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. regarding potential violations of federal securities laws. The investigation concerns whether the company and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. This scrutiny follows a significant drop in the company's stock price and the release of its first-quarter financial results for 2026.
On May 12, 2026, TriSalus reported revenue of $8.90 million, a decline of 2.92% year over year. Following this announcement, the company reduced its full-year revenue guidance to a range of $54 million to $57 million. This revision represents a reduction of $5.5 million at the midpoint compared to prior guidance. The company attributed the cut to lower Q1 revenues from its commercial expansion and a delay in receiving FDA clearance for its TriNav Advance product.
Management disclosed that the FDA clearance process for TriNav Advance is running approximately 5 months past the 30-day MDUFA review goal. On this news, TriSalus's stock price fell $1.89 per share, or 41.56%, to close at $2.67 per share on May 13, 2026.
| Key Event | Detail |
|---|---|
| Q1 Revenue | $8.90 million (decline of 2.92% YoY) |
| Guidance Range | $54 million to $57 million |
| Guidance Reduction | $5.5 million at midpoint |
| Stock Price Drop | 41.56% to $2.67 per share |
| FDA Delay | TriNav Advance ~5 months past 30-day MDUFA goal |
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as a premier firm in the areas of corporate, securities, and antitrust class litigation. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss their rights.
What is the revised timeline expectation for FDA clearance of the TriNav Advance product?
How will the company manage cash burn and operations given the reduced revenue guidance?
What specific steps is management taking to mitigate the impact of the commercial expansion delays?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
